or Try an Advanced Search...

    Technical Analysis for RGLS - Regulus Therapeutics Inc.

    Grade Last Price % Change Price Change
    B 2.26 2.73% 0.06
    RGLS closed up 2.73 percent on Tuesday, April 23, 2024, on 3 percent of normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 9
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical RGLS trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Support Bullish 2.73%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.73%
    Lower Bollinger Band Walk Weakness 2.73%
    Strong but Oversold Other 2.73%
    Wide Bands Range Expansion 2.73%
    Lower Bollinger Band Touch Weakness 2.73%
    Older End-of-Day Signals for RGLS ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 16 hours ago
    60 Minute Opening Range Breakout about 16 hours ago
    Non-ADX 1,2,3,4 Pullback Entry about 16 hours ago
    Rose Above Previous Day's High about 16 hours ago
    Up 3% about 16 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    RGLS Chart by TradingView
    Basic chart:

    Profile

    Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Disease Genetics Blastoma Glioblastoma Carcinoma Hepatitis C Hepatitis C Virus Oligonucleotide Hepatocellular Carcinoma RNA Regulus Therapeutics Nucleic Acids Alnylam Pharmaceuticals Atherosclerosis Hepatitis C Virus Infection Nucleotides

    Is RGLS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 10 Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD
    Apr 9 Regulus files to sell 62.5M shares of common stock for holders
    Mar 23 Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
    Mar 21 Regulus Therapeutics GAAP EPS of -$0.40 in-line
    Mar 21 Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
    Mar 14 Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
    Mar 13 Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
    Mar 12 Regulus Therapeutics stock up on $100M private placement of equity
    Mar 12 Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
    Mar 12 Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    See more RGLS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.79
    52 Week Low 1.08
    Average Volume 3,849,907
    200-Day Moving Average 1.56
    50-Day Moving Average 2.13
    20-Day Moving Average 2.59
    10-Day Moving Average 2.47
    Average True Range 0.24
    RSI (14) 44.75
    ADX 29.53
    +DI 19.44
    -DI 21.37
    Chandelier Exit (Long, 3 ATRs) 2.28
    Chandelier Exit (Short, 3 ATRs) 2.81
    Upper Bollinger Bands 3.06
    Lower Bollinger Band 2.12
    Percent B (%b) 0.15
    BandWidth 36.35
    MACD Line 0.01
    MACD Signal Line 0.11
    MACD Histogram -0.0974
    Fundamentals Value
    Market Cap 45.7 Million
    Num Shares 20.2 Million
    EPS -1.59
    Price-to-Earnings (P/E) Ratio -1.42
    Price-to-Sales 7.43
    Price-to-Book 1.12
    PEG Ratio -0.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.58
    Resistance 3 (R3) 2.57 2.45 2.52
    Resistance 2 (R2) 2.45 2.37 2.46 2.50
    Resistance 1 (R1) 2.36 2.32 2.41 2.37 2.49
    Pivot Point 2.24 2.24 2.27 2.25 2.24
    Support 1 (S1) 2.15 2.16 2.20 2.16 2.03
    Support 2 (S2) 2.03 2.11 2.04 2.02
    Support 3 (S3) 1.94 2.03 2.00
    Support 4 (S4) 1.95